Arbutus Biopharma vs Moderna Which Outperforms?

Arbutus Biopharma and Moderna are two companies in the biopharmaceutical industry that have garnered considerable attention from investors in recent years. Arbutus Biopharma focuses on developing therapeutics for infectious diseases, while Moderna is renowned for its innovative mRNA technology in creating vaccines and other treatments. As the demand for biopharmaceutical products continues to grow, investors are closely monitoring the performance of these two companies' stocks to capitalize on potential opportunities in the market.

Arbutus Biopharma or Moderna?

When comparing Arbutus Biopharma and Moderna, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Arbutus Biopharma and Moderna.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Arbutus Biopharma has a dividend yield of -%, while Moderna has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Arbutus Biopharma reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Moderna reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Arbutus Biopharma P/E ratio at -9.27 and Moderna's P/E ratio at -7.19. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Arbutus Biopharma P/B ratio is 6.65 while Moderna's P/B ratio is 1.34.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Arbutus Biopharma has seen a 5-year revenue growth of 0.02%, while Moderna's is 10.87%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Arbutus Biopharma's ROE at -68.18% and Moderna's ROE at -17.68%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $3.67 for Arbutus Biopharma and $41.06 for Moderna. Over the past year, Arbutus Biopharma's prices ranged from $1.98 to $4.72, with a yearly change of 138.38%. Moderna's prices fluctuated between $35.80 and $170.47, with a yearly change of 376.17%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.